// App-Quantinova.ai

: Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial

Researchers

Presenter

  • Gisli Jenkins

Principal Investigators

  • Toby M Maher

  • Vincent Cottin

  • Yasuhiko Nishioka

  • Imre Noth

  • Eric S White

  • Carina Ittrich

  • Claudia Diefenbach

  • Klaus B Rohr

  • Susanne Stowasser

  • Moiss Selman

Medical Centers

  • National Institute for Health Research Respiratory Biomedical Research Centre, City Campus, Nottingham University Hospital, Nottingham, United Kingdom.

  • National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom

  • Respiratory Diseases Department, National Reference Center for Rare Pulmonary Diseases, Respiratory Diseases Department, Louis Pradel Hospital, Claude Bernard Lyon 1 University, Lyon, France,

  • Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan

  • Division of Pulmonary & Critical Care Medicine, University of Virginia, Charlottesville, VA, United States,

  • University of Michigan, Division of Pulmonary & Critical Care Medicine, Ann Arbor, MI, United States,

  • Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico

Locations

  • United Kingdom

  • France

  • Japan

  • United States

  • Germany

  • Mexico

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved